Gyromitrin poisoning results from ingestion of Gyromitra esculenta ("false morel") and related species. The toxin gyromitrin is hydrolyzed in vivo to N-methyl-N-formylhydrazine (MFH) and then to monomethylhydrazine (MMH), which inhibits pyridoxal phosphate-dependent enzymes including glutamic acid decarboxylase (GAD), depleting GABA and causing seizures, while also producing direct hepatotoxicity via cytochrome P-450 disruption and lipid peroxidation. [1-4] Symptom onset is characteristically delayed 6–12 hours, distinguishing it from benign GI mushroom syndromes. [5-6]
1. History
- "Did you eat wild mushrooms?" — the single most critical question; often missed on initial presentation [7]
- Species identification: Gyromitra ("false morel") vs. Morchella ("true morel") — false morels have a brain-like, irregularly lobed cap vs. the honeycomb-pitted cap of true morels [8]
- Preparation method: raw, undercooked, or dried? Boiling with water exchange reduces hydrazine content by ~94–97%, but residual toxin may persist [9]
- Timing: symptom onset typically 6–12 hours post-ingestion (median 9 h, IQR 6–12 h) [5]
- Quantity consumed and whether others ate the same meal (cluster cases)
- Prior consumption history — repeated ingestion increases cumulative toxicity and may sensitize [10]
- Progression: initial GI symptoms → hepatic/neurologic symptoms over 24–72 hours [1]
2. Alarm Features
- Seizures — reported in ~14% of Gyromitra ingestions, but present in 82% of fatal cases as a late finding after coma onset [5]
- Jaundice developing 24–48 hours after ingestion → hepatic failure
- Altered mental status, coma
- Refractory vomiting with hemodynamic instability
- Coagulopathy (elevated INR) suggesting fulminant hepatic failure
- Methemoglobinemia (rare, from MMH oxidant stress)
- Hemolysis (reported in only ~2.5% of cases) [5]
- Multi-organ failure
3. Medications
- Pyridoxine (Vitamin B6) — the specific antidote for neurotoxicity/seizures
- Dose: 25 mg/kg IV (commonly cited empiric dose); may repeat as needed
- Mechanism: replenishes pyridoxal phosphate, restoring GAD activity and GABA synthesis [3][11]
- Used in 8.4% of symptomatic patients in a large Michigan series, specifically those with hepatotoxicity or neurotoxicity [8]
- Benzodiazepines (diazepam, lorazepam) — first-line for acute seizure control; synergistic with pyridoxine at the GABA receptor [12]
- Activated charcoal — if presenting within 1–2 hours of ingestion (rarely feasible given delayed presentation) [13]
- Antiemetics (ondansetron) for refractory vomiting
- N-acetylcysteine (NAC) — may be considered empirically for hepatotoxicity (extrapolated from other hepatotoxic ingestions; no controlled data specific to gyromitrin)
- Contraindicated: avoid hepatotoxic medications; no role for silibinin (specific to amatoxin poisoning) [13]
4. Diet
- NPO during acute illness with active vomiting or hepatotoxicity
- Aggressive IV fluid resuscitation for dehydration from GI losses
- Correct electrolyte abnormalities (hypokalemia, hyponatremia)
- Long-term: counsel against consumption of Gyromitra species; even traditional preparation methods (boiling, drying) do not guarantee safety — residual toxins persist [9]
- Inhalation of cooking vapors from boiling false morels can also cause toxicity
5. Review of Systems
- GI: nausea, vomiting, watery diarrhea, abdominal cramping (74.7% of symptomatic cases) [8]
- Neurologic: headache, dizziness, tremor, ataxia, seizures, coma (26.5%) [8]
- Hepatic: RUQ pain, jaundice (16.9%) [8]
- Hematologic: dark urine (hemolysis/methemoglobinemia — rare) [5]
- Renal: decreased urine output (secondary to hepatorenal syndrome or direct renal effects) [11]
- Constitutional: fatigue, malaise, fever
6. Collateral History and Family History
- Co-ingestors: identify all individuals who shared the mushroom meal — cluster presentations are common and help confirm the diagnosis [7]
- Obtain leftover mushroom specimens or photographs for mycologist identification [6]
- Foraging experience and geographic location (spring season, coniferous forests)
- Genetic variability: individual acetylator status may influence susceptibility — slow acetylators may produce more MMH from MFH, increasing toxicity [10][14]
- No hereditary predisposition per se, but family members are often co-exposed
7. Risk Factors
- Misidentification of Gyromitra as edible Morchella (true morel) — the most common cause of exposure [8]
- Consumption of raw or undercooked false morels [7]
- Spring foraging season (March–May in Northern Hemisphere)
- Geographic: Northern Europe, Great Lakes region (Michigan), Pacific Northwest [7-8]
- Repeated/cumulative ingestion over time [10]
- Children — higher susceptibility due to lower body mass
- Slow acetylator phenotype (theoretical increased risk) [14]
8. Differential Diagnosis
- Amatoxin poisoning (Amanita phalloides) — the most dangerous mimic; also presents with delayed GI symptoms (6–12 h) followed by hepatic failure; distinguished by more severe/fulminant hepatotoxicity and lack of early seizures; urine amatoxin testing available [6][13]
- Orellanine poisoning (Cortinarius spp.) — very delayed nephrotoxicity (days to weeks) [15]
- Viral gastroenteritis / food poisoning — shorter latency, no hepatotoxicity; easily confused on initial presentation [7]
- Acetaminophen overdose — delayed hepatotoxicity; check levels
- Isoniazid toxicity — also causes pyridoxine-responsive seizures; medication history distinguishes
- Other hepatotoxic ingestions (carbon tetrachloride, yellow phosphorus)
- Acute viral hepatitis (HAV, HBV, HEV) [16]
9. Past Medical History
- Pre-existing liver disease (cirrhosis, hepatitis) — increases vulnerability to hepatotoxicity
- Prior episodes of mushroom poisoning
- Chronic alcohol use (impaired hepatic reserve)
- Medications affecting hepatic metabolism (CYP450 inducers may increase toxic metabolite formation) [2]
- Renal disease (impaired clearance)
10. Physical Exam
- Vitals: tachycardia, hypotension (from dehydration or shock); fever possible
- Abdomen: diffuse tenderness, especially epigastric/RUQ; hepatomegaly in severe cases
- Skin/Eyes: jaundice (24–72 h post-ingestion); cyanosis if methemoglobinemia present
- Neuro: altered mental status, tremor, ataxia, hyperreflexia, seizures, coma (late)
- Mucous membranes: dry (dehydration)
- Liver edge: tender, enlarged
11. Lab Studies
- Hepatic panel: AST, ALT (may rise dramatically 24–48 h post-ingestion), total/direct bilirubin, alkaline phosphatase [1]
- Coagulation: PT/INR — critical marker of hepatic synthetic function and severity
- CBC: evaluate for hemolytic anemia (rare, ~2.5%); leukocytosis [5]
- BMP/CMP: electrolytes, glucose (hypoglycemia in hepatic failure), BUN/creatinine
- Methemoglobin level — if cyanosis or low SpO2 with normal PaO2
- Lactate — marker of tissue hypoperfusion
- Ammonia — if encephalopathy suspected
- Urinalysis — hemoglobinuria
- Blood type and screen — in anticipation of possible transfusion or liver transplant evaluation
- Acetaminophen level, salicylate level — to rule out co-ingestion
- Viral hepatitis serologies (HAV IgM, HBsAg, HBc IgM, HCV RNA) — to exclude competing diagnoses [16]
12. Imaging
- RUQ ultrasound — assess liver echotexture, hepatomegaly, biliary obstruction
- CT abdomen — if concern for alternative surgical pathology or complications
- Imaging is generally not diagnostic for gyromitrin poisoning but helps exclude other etiologies
- Chest X-ray — if respiratory symptoms or aspiration concern from vomiting/seizures
13. Special Tests
- Mushroom identification by a trained mycologist — the most important diagnostic step; examine leftover specimens, spore prints, or photographs [6][17]
- Spore analysis of gastric contents or stool (if available)
- Gyromitrin/MMH analytical detection — rarely available clinically; limited analytical methods exist in biological matrices [17]
- LAMP-based molecular identification of Gyromitra species has been developed for rapid identification [18]
- Poison Control Center consultation — essential for all suspected cases
14. ECG
- Obtain baseline ECG to evaluate for:
- QTc prolongation (electrolyte derangements from vomiting/diarrhea)
- Dysrhythmias secondary to metabolic derangements (hyperkalemia, hypokalemia)
- No pathognomonic ECG findings for gyromitrin poisoning
- Serial ECGs if hemodynamically unstable
15. Assessment
Gyromitrin poisoning follows a biphasic clinical course: [1][5]
- Phase 1 (6–12 h): Predominantly GI — nausea, vomiting, watery diarrhea, abdominal pain (88% of cases)
- Phase 2 (24–72 h): Hepatotoxicity (elevated transaminases, jaundice, coagulopathy — 54% in literature review) and/or neurotoxicity (headache, dizziness, ataxia, seizures, coma — 52%)
- Severe cases: Fulminant hepatic failure, renal failure, DIC, multi-organ failure, death
Mortality in published literature is ~29% for Gyromitra ingestions, though this reflects publication bias toward severe cases; a large poison center series reported no deaths among 118 cases. [5][8] Seizures are a late and ominous finding, occurring mostly in fatal cases after coma onset. [5]
16. Treatment Plan
Initial Stabilization
- ABCs; IV access, cardiac monitoring, continuous pulse oximetry
- Aggressive IV crystalloid resuscitation for volume depletion
- Activated charcoal 1 g/kg if within 1–2 hours of ingestion (rarely applicable)
Specific Antidote
- Pyridoxine (Vitamin B6): 25 mg/kg IV for seizures or significant neurotoxicity; may repeat [8][11]
- Administer empirically if seizures occur in the setting of suspected mushroom ingestion
- Also consider prophylactic pyridoxine in patients with confirmed Gyromitra ingestion and any neurologic symptoms
Seizure Management
- Benzodiazepines (lorazepam 0.1 mg/kg IV or diazepam 0.2 mg/kg IV) as first-line adjunct [12]
- Pyridoxine-refractory seizures: escalate per status epilepticus protocols
Hepatotoxicity Management
- Serial LFTs and coagulation studies every 6–12 hours
- NAC may be considered empirically (no specific evidence for gyromitrin, but low risk)
- Correct coagulopathy with FFP/vitamin K if actively bleeding or INR critically elevated
- Hepatology and transplant surgery consultation early if evidence of fulminant hepatic failure
- Liver transplantation may be required in refractory cases [13]
Methemoglobinemia (if present)
Supportive
- Antiemetics (ondansetron)
- Correct electrolytes and glucose
- Monitor for DIC, renal failure
17. Disposition
- Admit (ICU preferred) all patients with:
- Confirmed Gyromitra ingestion with any symptoms
- Elevated transaminases or coagulopathy
- Neurologic symptoms (altered mental status, seizures)
- Hemodynamic instability
- Observation (minimum 24 hours): asymptomatic patients with confirmed or suspected ingestion — hepatotoxicity may be delayed 24–48 hours [6]
- Discharge only if: asymptomatic after 24-hour observation, normal labs including LFTs and coagulation, reliable follow-up
- Consult: Poison Control, toxicology, hepatology (if hepatotoxicity), mycologist for species identification
18. Follow Up / Return Precautions
- Follow-up LFTs at 48–72 hours post-discharge, then weekly until normalized
- Return immediately for: recurrent vomiting, abdominal pain, jaundice, dark urine, confusion, seizures, bleeding
- Counsel on expected recovery: mild cases resolve within days; hepatotoxicity may take 1–2 weeks to fully resolve
- Patient education: never consume Gyromitra species; even traditional preparation (boiling, drying) does not guarantee safety; avoid inhaling cooking vapors [9]
- Educate on distinguishing true morels (Morchella) from false morels (Gyromitra) — when in doubt, do not eat wild mushrooms
- Report to local Poison Control Center for epidemiologic tracking
References
1. Poisoning by Gyromitra Esculenta--a Review. — Michelot D, Toth B. Journal of Applied Toxicology : JAT. 1991.
2. Liver Injury by the False Morel Poison Gyromitrin. — Braun R, Greeff U, Netter KJ. Toxicology. 1979.
3. Slow-Binding Inhibition of Gamma-Aminobutyric Acid Aminotransferase by Hydrazine Analogues. — Lightcap ES, Silverman RB. Journal of Medicinal Chemistry. 1996.
4. Formation of Methylhydrazine From Acetaldehyde N-Methyl-N-Formylhydrazone, a Component of Gyromitra Esculenta. — Nagel D, Wallcave L, Toth B, Kupper R. Cancer Research. 1977.
5. A Narrative Review of Toxicity After Exposure to True Morel (Morchella Genus) and False Morel (Gyromitra Genus) Mushroom Ingestions. — Simon MW, Kuai D, Yeh M, Yip L. Clinical Toxicology. 2025.
6. Mushroom Poisoning. — Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Deutsches Arzteblatt International. 2020.
7. Poisoning Due to Raw Gyromitra Esculenta (False Morels) West of the Rockies. — Leathem AM, Dorran TJ. Cjem. 2007.
8. A 19-Year Longitudinal Assessment of Gyromitrin-Containing (Gyromitra Spp.) Mushroom Poisonings in Michigan. — Vohra V, Dirks A, Bonito G, James T, Carroll DK. Toxicon : Official Journal of the International Society on Toxinology. 2024.
9. Monomethylhydrazine Content Is Determined by Altitude in Gyromitra Antarctica: Implications for Safe Consumption. — Parada RB, Garibay Orijel R, de Errasti A, Pildain MB, Barroetaveña C. Mycologia. 2026.
10. Poisoning by Gyromitra : A Possible Mechanism. — Coulet M, Guillot J. Medical Hypotheses. 1982.
11. Renal Functional Response to the Mushroom Poison Gyromitrin. — Braun R, Kremer J, Rau H. Toxicology. 1979.
12. Modulation of Monomethylhydrazine-Induced Seizures by Ivermectin. — Mayer TW, Horton ML. Toxicology Letters. 1991.
13. Clinical Symptomatology and Management of Mushroom Poisoning. — Köppel C. Toxicon : Official Journal of the International Society on Toxinology. 1993.
14. Methylation of Rat and Mouse DNA by the Mushroom Poison Gyromitrin and Its Metabolite Monomethylhydrazine. — Bergman K, Hellenäs KE. Cancer Letters. 1992.
15. Mushroom Poisoning: A Proposed New Clinical Classification. — White J, Weinstein SA, De Haro L, et al. Toxicon : Official Journal of the International Society on Toxinology. 2019.
16. AASLD Practice Guidance on Drug, Herbal, and Dietary Supplement-Induced Liver Injury. — Fontana RJ, Liou I, Reuben A, et al. Hepatology. 2023.
17. Human Poisoning From Poisonous Higher Fungi: Focus on Analytical Toxicology and Case Reports in Forensic Toxicology. — Flament E, Guitton J, Gaulier JM, Gaillard Y. Pharmaceuticals. 2020.
18. Identification of Gyromitra Infula: A Rapid and Visual Method Based on Loop-Mediated Isothermal Amplification. — Xie X, Li B, Fan Y, et al. Frontiers in Microbiology. 2021.